Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.
Company profile
Ticker
RYTM
Exchange
Website
CEO
Hunter Smith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RHYTHM METABOLIC, INC.
SEC CIK
Corporate docs
Subsidiaries
Rhythm Pharmaceuticals Limited • Rhythm Securities Corp. • Rhythm Pharmaceuticals Netherlands, B.V. • Rhythm Pharmaceuticals UK Limited • Rhythm Pharmaceuticals France SAS • Rhythm Pharmaceuticals Italy S.r.L. • Rhythm Pharmaceuticals Canada Inc. ...
RYTM stock data
Analyst ratings and price targets
Current price
Average target
$33.00
Low target
$26.00
High target
$40.00
Goldman Sachs
Maintains
$40.00
Morgan Stanley
Maintains
$26.00
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
9 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
8 Nov 22
8-K
Termination of a Material Definitive Agreement
3 Nov 22
8-K
Other Events
15 Sep 22
424B5
Prospectus supplement for primary offering
15 Sep 22
424B5
Prospectus supplement for primary offering
14 Sep 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
2 Aug 22
8-K
Entry into a Material Definitive Agreement
16 Jun 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 185.42 mm | 185.42 mm | 185.42 mm | 185.42 mm | 185.42 mm | 185.42 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 13.09 mm | 15.67 mm | 15.66 mm | 14.99 mm |
| Cash used (since last report) | n/a | n/a | 55.27 mm | 66.17 mm | 66.14 mm | 63.31 mm |
| Cash remaining | n/a | n/a | 130.14 mm | 119.24 mm | 119.28 mm | 122.11 mm |
| Runway (months of cash) | n/a | n/a | 9.9 | 7.6 | 7.6 | 8.1 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 103 |
| Opened positions | 37 |
| Closed positions | 25 |
| Increased positions | 35 |
| Reduced positions | 18 |
| 13F shares | Current |
|---|---|
| Total value | 1.43 bn |
| Total shares | 60.07 mm |
| Total puts | 443.00 k |
| Total calls | 1.03 mm |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Primecap Management | 7.03 mm | $172.16 mm |
| FHI Federated Hermes | 6.31 mm | $154.52 mm |
| Baker Bros. Advisors | 6.06 mm | $148.54 mm |
| Ra Capital Management | 5.47 mm | $134.04 mm |
| NEA Management | 4.91 mm | $108.32 mm |
| GS Goldman Sachs | 4.78 mm | $117.04 mm |
| BLK Blackrock | 3.54 mm | $86.67 mm |
| Vanguard | 2.23 mm | $54.74 mm |
| Frazier Life Sciences Management | 1.89 mm | $46.40 mm |
| Flynn James E | 1.87 mm | $18.64 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Feb 23 | Jennifer Chien | Stock Option Common Stock | Grant | Acquire A | No | No | 27.35 | 46,900 | 1.28 mm | 46,900 |
| 1 Feb 23 | Jennifer Chien | RSU Common Stock | Grant | Acquire A | No | No | 0 | 18,050 | 0.00 | 18,050 |
| 1 Feb 23 | Yann Mazabraud | RSU Common Stock | Grant | Acquire A | No | No | 0 | 41,500 | 0.00 | 41,500 |
| 1 Feb 23 | Pamela J. Cramer | Stock Option Common Stock | Grant | Acquire A | No | No | 27.35 | 26,800 | 732.98 k | 26,800 |
| 1 Feb 23 | Pamela J. Cramer | RSU Common Stock | Grant | Acquire A | No | No | 0 | 10,600 | 0.00 | 10,600 |
| 1 Feb 23 | Meeker David P | Stock Option Common Stock | Grant | Acquire A | No | No | 27.35 | 229,600 | 6.28 mm | 229,600 |
| 1 Feb 23 | Meeker David P | RSU Common Stock | Grant | Acquire A | No | No | 0 | 56,500 | 0.00 | 56,500 |
| 1 Feb 23 | Joseph Shulman | Stock Option Common Stock | Grant | Acquire A | No | No | 27.35 | 33,500 | 916.23 k | 33,500 |
| 1 Feb 23 | Joseph Shulman | RSU Common Stock | Grant | Acquire A | No | No | 0 | 15,750 | 0.00 | 15,750 |
News
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $40
26 Jan 23
Rhythm Pharmaceuticals Announces Publication Of Analysis Of Quality Of Life Improvements From Phase 3 Clinical Trial In Bardet-Biedl Syndrome
23 Jan 23
Canaccord Genuity Assumes Rhythm Pharmaceuticals at Buy
18 Jan 23
Rhythm Pharmaceuticals's Return On Capital Employed Overview
6 Dec 22
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $35
10 Nov 22
Press releases
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
5 Jan 23
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
7 Dec 22
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
8 Nov 22
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
7 Nov 22